Where does phototherapy fit in psoriasis care?
Compare the main treatment categories, where medical phototherapy fits, and which tradeoffs belong in a psoriasis conversation.
Last updated
Start with the categories and the goal
Psoriasis care can include supportive skin care, topical medicines, medical phototherapy, oral systemic medicines, injected biologics and infused biologics. The discussion should start with skin and joint goals, affected sites, life impact, medical history, monitoring, route, prior response, access and preference - not a universal sequence. Evidence Evidence Evidence
What the sources support
NIAMS, AAD/NPF and NICE describe multiple treatment categories and make assessment, impact and individual context part of treatment choice.
What remains individual or uncertain
A category map is not complete product guidance. It cannot rank personal fit, likely benefit, risk, burden, access or cost.
Questions for your clinician
- What goal are we treating: skin symptoms, clearing, joint disease or several goals? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which treatment categories are reasonable for that goal? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Which medical, practical or access factor could change the comparison? Saving keeps this on your device and needs JavaScript, which is off in this browser.
What belongs in the oral-medicine conversation?
Oral options include conventional and targeted medicines. Icotyde (icotrokinra) is not investigational in the United States. FDA approved it in March 2026 for moderate-to-severe plaque psoriasis. The approved population is adults and adolescents ages 12 and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Evidence Evidence Evidence Evidence Evidence
What the sources support
The current FDA label establishes the approval, oral route, labeled population and product-specific precautions. Guidelines and patient education describe other oral options, including methotrexate, apremilast, deucravacitinib and acitretin.
What remains individual or uncertain
Approval does not establish that icotrokinra is best, safer than another option, suitable for a particular reader, covered by insurance or supported by mature postmarketing experience. This list is not complete or comparative.
Questions for your clinician
- Which oral options belong in my comparison, and why? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What product-specific monitoring, infection, vaccine or pregnancy questions apply? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- How would access and prior authorization affect continuity? Saving keeps this on your device and needs JavaScript, which is off in this browser.
How are biologics and biosimilars organized?
Biologics used in psoriasis are commonly grouped by the immune pathway they target, including TNF, IL-12/23, IL-17 and IL-23 therapies. Some are injected and some are infused. FDA-approved biosimilars are highly similar to a reference biologic and have no clinically meaningful differences in safety and effectiveness. Evidence Evidence Evidence
What the sources support
Clinical guidance recognizes multiple biologic classes. FDA defines the evidence standard for an approved biosimilar, while each product keeps its own label, indication and administration details.
What remains individual or uncertain
A pathway label does not make medicines interchangeable or equally suitable. This page does not compare clearance rates, rare harms, long-term safety, exact indications, availability or coverage.
Questions for your clinician
- Which pathway classes fit the skin and joint goals we identified? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Would this be self-injected or infused, and what support would it require? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Is a biosimilar relevant, and which exact product label applies? Saving keeps this on your device and needs JavaScript, which is off in this browser.
What can medical phototherapy treat?
Medical narrowband UVB can treat psoriasis in the skin. It does not treat inflammation in the joints and is not a treatment for psoriatic arthritis. Tanning beds and casual sunlight are not substitutes for prescribed, medically supervised phototherapy. Evidence Evidence Evidence
What the sources support
Phototherapy guidance supports clinician-directed NB-UVB for selected skin disease. Psoriatic arthritis guidance describes separate clinical assessment and treatments for joint and tendon inflammation.
What remains individual or uncertain
This boundary does not decide whether phototherapy fits your skin, compare it with a systemic option or provide a treatment setting. Skin and joint needs may require coordinated plans.
Questions for your clinician
- What skin goal could phototherapy address for me? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- What makes medical phototherapy different from a tanning bed or casual sunlight? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- If joint disease is suspected, who evaluates and treats it separately? Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if I also have joint, tendon or nail concerns?
Tell a clinician about joint pain or swelling, stiffness, tendon-area symptoms and nail changes. Those concerns may need a separate clinical assessment; this page is not a screening result. Evidence
What the sources support
NIAMS describes diagnosis as a clinical process that considers symptoms, examination and other tests when needed.
What remains individual or uncertain
Symptoms can have many causes. A web checklist cannot confirm or rule out psoriatic arthritis.
Questions for your clinician
- Could these joint, tendon or nail changes need a separate assessment? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Who should assess them? Saving keeps this on your device and needs JavaScript, which is off in this browser.
- Would those concerns change which treatment categories we discuss? Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a broad patient-facing map of topical treatment, phototherapy, oral systemic treatment and biologic treatment.
What it does not support
It does not rank categories or choose treatment for a particular person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The guideline reports author relationships; it is not independent comparative proof for an individual choice.
What this source supports
Supports that methotrexate, apremilast, cyclosporine and acitretin are established systemic nonbiologic options considered in psoriasis care.
What it does not support
It does not select, rank or prescribe an option for an individual reader.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute for Health and Care ExcellenceGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports psoriasis assessment across skin, nails, high-impact sites, life impact and joint concerns; same-day specialist assessment for generalised pustular psoriasis or erythroderma; and a treatment map that includes topical, phototherapy and systemic options.
What it does not support
It is UK guidance and does not diagnose a reader, create a US treatment sequence, determine personal urgency from a description, or establish current US labeling or coverage.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Psoriasis FoundationPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The organization provides patient education, but its editorial and funding independence for this page was not independently reviewed. It is used only for patient-facing treatment-category context.
What this source supports
Supports patient-facing context that methotrexate, apremilast, deucravacitinib and acitretin are real oral treatment options discussed in psoriasis care.
What it does not support
It does not determine personal suitability, comparative benefit, coverage or a treatment sequence.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: FDA-approved prescribing information is authoritative for US labeling; it is product-specific regulator-approved labeling, not independent comparative clinical evidence.
What this source supports
Supports the current FDA-approved labeled plaque-psoriasis population, oral route, IL-23 receptor mechanism, and label precautions for Icotyde (icotrokinra).
What it does not support
The label states only “Revised: 3/2026”; it does not establish an exact revision day or the approval-action date. It also does not establish comparative superiority, personal suitability, insurance coverage, mature postmarketing evidence, or a class-wide conclusion. SteadySkin does not reproduce its regimen.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the exact US FDA approval action date for Icotyde (icotrokinra).
What it does not support
The approval list does not establish the full labeled population, comparative superiority, personal suitability, insurance coverage, or postmarketing experience.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports only that the FDA approval-package cover for NDA 220149 records an approval date of March 18, 2026 and identifies the approved indication.
What it does not support
The package does not explain or reconcile why the separate FDA Novel Drug Approvals for 2026 table records March 17, 2026. SteadySkin preserves that one-day discrepancy and does not use either record as evidence for what the other records.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- U.S. Food and Drug AdministrationRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the FDA definition that an approved biosimilar is highly similar to its reference product with no clinically meaningful differences in safety and effectiveness.
What it does not support
It does not establish that every biologic has a biosimilar, transfer an indication between products, choose a product, or determine substitution, coverage, availability, or personal response.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Goulden V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
It supports that traditional NB-UVB fluorescent lamps emit a narrow UVB band peaking around 311 nanometres. It backs wearing UV-protective goggles and keeping UV scatter off people nearby. It records the consent form naming goggles and the same clothing at each session. It also covers clinical uses, how it compares with other light treatments, safety limits including sunburn-type reactions, and the added safeguards home phototherapy needs.
What it does not support
It does not provide a personal treatment plan, approve a particular home setup, or replace the instructions for your own device. SteadySkin never reproduces its treatment schedules.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Association of DermatologistsPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
It supports a plain-language explanation that NB-UVB uses a small part of the UVB spectrum, is used for conditions including psoriasis, eczema, and vitiligo, and is distinct from sunlight or a sunbed. It also supports what a unit asks of its own patients during a course. It asks them not to sunbathe or use a sunbed for the whole of it, and to reduce sun exposure so that skin does not burn. It asks them to report a medicine, a cream, or newly exposed skin such as a haircut. It asks them to arrive without perfume, deodorant, aftershave or other cosmetics, because some of those raise light sensitivity and can leave patchy discolouration for months. It carries the unit’s own account of repeated courses. It states that the full risk of narrowband UVB is not known, and that roughly one in ten people in the UK develop skin cancer. It states that a review becomes usual practice past a stated number of treatments, and that many treatments can bring the wrinkling and discolouration of photoageing.
What it does not support
It is patient education, not primary evidence for an efficacy claim. Its printed next review date was June 2025 and it has not been updated since June 2022. It is therefore used only for what it plainly states, and never as current guidance. It is written for a UK hospital unit whose nurses examine skin at every visit, so it sets no rule for a device used at home. Its numbers stay in this record rather than in the copy. Those are the sun protection factor and star rating it names, the hours it names, the treatment count that triggers a review, and the multiple by which it estimates lifetime risk. That multiple is stated there as an assumption that narrowband UVB behaves like sunlight, not as a measurement.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports bringing joint, tendon, swelling, stiffness and nail concerns to a clinician because diagnosis uses clinical assessment and may require further evaluation.
What it does not support
It is not an online screening result and cannot diagnose psoriatic arthritis from a checklist.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.